達(dá)比加群酯治療腦梗死合并房顫的效果及對安全性的影響

打開文本圖片集

[Abstract]Objective：Toexplore theeficacyDabigatran Etexilatein thetreatmentcerebral infarction complicatedwithatrial fibrillationanditsinfluenceonsafety.Method：Atotal8Opatients withcerebral infarction complicated withatrial fibrilationwho wereadmitted inLeping People's Hospital from April2023 to May 2024 were selected and divided into the control group （treated with Warfarin and Rivaroxaban， n=40 ） and the study group （treated with Dabigatran Etexilate， n=40 ）according to the random number table method.The clinical efficacy， seven items coagulation，inflammatory response and occurrence adverse events the two groups were evaluated.Result：The total clinical efectiverate in the study group was higher thanthatinthecontrol group，and theincidence adverse events was lower than that inthecontrol group，the differences were statisticallsignificant 0 P <0.05）.After the treatment，the levels the seven items coagulationand inflammatory factor indicators in the study group were better than those in the control group，the diferences were statistically significant （ P <0.05）. Conclusion： Dabigatran Etexilate has aremarkable effect inthe treatment cerebral infarction complicated with atrial fibrillation.The coagulation functionand inflammatoryresponse have beensignificantlyimproved，andtherisk adverse events is relatively low.

[Keywords] DabigatranEtexilateCerebral infarction Atrial fibrillation Seven items coagulation Inflammatory responseAdverse events

First-author'saddress：DepartmentNeurology，LepingPeople'sHospital，Leping33oo， doi：10.3969/j.issn.1674-4985.2025.22.005

腦梗死主要是由缺血、缺氧誘發(fā)的腦組織局限性缺血性壞死、軟化[-2]。（剩余5099字）